

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Barnardo, et al.

Appl. No. 10/623,802

Filed: 07/22/2003

For: METHOD

Confirmation No.: 5302

Art Unit: 1641

Examiner: Gary W. Counts

Atty. Docket: 1181-282

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

To the Examiner:

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

CITED REFERENCES

U.S. Patents

4,810,632 (McMillan)

5,110,726 (Ogden)

5,180,661 (Brubaker)

5,270,169 (Chang)

5,292,641 (Pouletty)

Other Documents:

Altman, et al. Formation of functional peptide complexes of class II major histocompatibility complex proteins from subunits produced in *Escherichia coli*. PNAS USA 90: 10330-10334 (Nov. 1, 1993)

Austin, et al. Functional expression of HLA-DP genes transfected into mouse fibroblasts. Nature 313(5997): 61-64 (1985)

Claesson-Welsh, et al. Implications of the invariant gamma-chain on the intracellular transport of class II histocompatibility antigens. J. Immunol. 135(5): 3551-3557 (1985)

Gauthier, et al. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. PNAS 95(20): 11828-11833 (Sept. 29, 1998)

Koppelman, et al. Rapid nonlysosomal degradation of assembled HLA class II glycoproteins incorporating a mutant DR alpha-chain. J. Immunol. 145 (8), 2730-2736 (1990)

Kvist, et al. Membrane insertion and oligomeric assembly of HLA-DR histocompatibility antigens. Cell, Vol 29, 61-69, May 1982

Lawrance, et al. The genomic organisation and nucleotide sequence of the HLA-SB(DP) alpha gene. Nucleic Acids Res. 13 (20): 7515-7528 (1985)

Long, et al. Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens. Proc. Natl. Acad. Sci. USA. 80(18): 5714-5718 (1983)

Marsh, et al. HLA class II nucleotide sequences, 1992. Tissue Antigens 40 (5), 229-243 (1992)

Miller, et al. Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. *J. Exp. Med.* 164: 1478-1489 (1986)

Schaff, et al. HLA-DR associates with specific stress proteins and is retained in the endoplasmic reticulum in invariant chain negative cells. *J. Exp. Med.* 176 (3), 657-666 (1992)

Stern, et al. The human class II MHC protein HLA-DR1 assembles as empty $\alpha\beta$ heterodimers in the absence of antigenic peptide. *Cell* 68: 465-477 (1992)

Tan, et al. A novel, highly efficient peptide-HLA class I binding assay using unfolded heavy chain molecules: identification of HIV-1 derived peptides that bind to HLA-A*0201 and HLA-A*0301. *J. Immunol. Meth.* 205: 201-209 (1997)

Wake, et al. Isolation of cDNA clones encoding HLA-DR alpha chains. *Proc. Natl. Acad. Sci. USA*, 79(22): 6979-6983 (1982)

Wettstein, et al. Expression of a Class II Major Histocompatibility Complex (MHC) Heterodimer in a Lipid-linked Form with Enhanced Peptide/Soluble MHC Complex Formation at Low pH. *J. Exp. Med.* 174: 219-228 (1991)

Young, et al. Epitope recognition by a DP alpha chain-specific monoclonal antibody (DP11.1) is influenced by the interaction between the DP alpha chain and its polymorphic DP beta chain partner. *Hum. Immunol.* 23(1): 37-44 (1988)

Respectfully Submitted,

Date: August 4, 2008

/Patrick J. Halloran/
Patrick J. Halloran

Patrick J. Halloran, Ph.D., J.D.
3141 Muirfield Road
Center Valley, PA 18034
Tel: 610-984-4751
Fax: 484-214-0164
pat@pathalloran.com